Glycine
|
Basic information |
| Metabolite name | Glycine |
 | HMDB0000123 |
 |
C00037 |
 |
750 |
| Synonyms | NA |
| No. of studies | 79 |
|
Basic information |
| Metabolite name | Glycine |
| HMDB0000123 |
|
C00037 |
|
750 |
| Synonyms | NA |
| No. of studies | 79 |
|
Relationship between Glycine and depression (count: 79) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M004 | Type2 | CUMS + amitriptyline group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M004 | Type2 | CUMS + xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M010 | Type4 | SSRI-treated responder group vs. non-responder group | Plasma | Human | Down |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M029 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M029 | Type2 | CUMS + BHD group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Up |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1043 | Type1 | late-life depression group vs. control group | Serum | Human | Up |
| Study M1049 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Up |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Down |
| Study M116 | Type3 | LY group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | R-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M545 | Type1 | LPS group vs. control group | Skeletal muscle | C57BL/6 mouse | Down |
| Study M545 | Type2 | LPS + ketamine group vs. LPS group | Skeletal muscle | C57BL/6 mouse | Up |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M671 | Type1 | CUMS group vs. control group | Striatum | Sprague-Dawley rat | Up |
| Study M676 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M676 | Type2 | CVS + Chaihu-Shu-Gan-San group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M721 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M755 | Type1 | high-dose D-ribose group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M830 | Type1 | corticosterone group vs. control group | Brain | Swiss mouse | Down |
| Study M830 | Type2 | corticosterone + acupoint catgut embedding group vs. corticosterone group | Brain | Swiss mouse | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Urine | Wistar rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M909 | Type3 | ketamine group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M935 | Type1 | chronic social isolation group vs. control group | Hippocampus | Wistar rat | Down |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |